A pharmaceutical company has received federal approval for a groundbreaking treatment targeting children who suffer from a rare genetic condition that results in dwarfism.
On Friday, the Food and Drug Administration granted authorization to Ascendis Pharma for their innovative once-weekly therapy, according to company officials. The treatment is specifically designed to help children diagnosed with the uncommon genetic disorder.
The newly approved medication represents a significant development in treating this rare condition that affects children’s growth and development.
